These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 31673326)

  • 21. Monitoring the manufacturing and quality of medicines: a fundamental task of pharmacovigilance.
    Sardella M; Belcher G; Lungu C; Ignoni T; Camisa M; Stenver DI; Porcelli P; D'Antuono M; Castiglione NG; Adams A; Furlan G; Grisoni I; Hall S; Boga L; Mancini V; Ciuca M; Chonzi D; Edwards B; Mangoni AA; Tuccori M; Prokofyeva E; De Gregorio F; Bertazzoli Grabinski Broglio M; van Leeuwen B; Kruger P; Rausch C; Le Louet H
    Ther Adv Drug Saf; 2021; 12():20420986211038436. PubMed ID: 34394910
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monitoring drug safety in Astrakhan, Russia.
    Kirilochev OO; Dorfman IP; Umerova AR
    Int J Risk Saf Med; 2015; 27 Suppl 1():S33-4. PubMed ID: 26639700
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacovigilance in Israel - tools, processes, and actions.
    Schwartzberg E; Berkovitch M; Dil Nahlieli D; Nathan J; Gorelik E
    Isr J Health Policy Res; 2017 Aug; 6(1):29. PubMed ID: 28760141
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A description of signals during the first 18 months of the EMA pharmacovigilance risk assessment committee.
    Pacurariu AC; Coloma PM; van Haren A; Genov G; Sturkenboom MC; Straus SM
    Drug Saf; 2014 Dec; 37(12):1059-66. PubMed ID: 25398646
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drugs for rare diseases: mixed assessment in Europe.
    Prescrire Int; 2007 Feb; 16(87):36-42. PubMed ID: 17323539
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identifying Safety Subgroups at Risk: Assessing the Agreement Between Statistical Alerting and Patient Subgroup Risk.
    Mahaux O; Powell G; Haguinet F; Sobczak P; Saini N; Barry A; Mustafa A; Bate A
    Drug Saf; 2023 Jun; 46(6):601-614. PubMed ID: 37131012
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Post-marketing safety surveillance of erenumab: new insight from Eudravigilance.
    Liang D; Sessa M
    Expert Opin Drug Saf; 2022 Sep; 21(9):1205-1210. PubMed ID: 35236231
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety of Perflutren Ultrasound Contrast Agents: A Disproportionality Analysis of the US FAERS Database.
    Hauben M; Hung EY; Hanretta KC; Bangalore S; Snow V
    Drug Saf; 2015 Nov; 38(11):1127-39. PubMed ID: 26242615
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Choosing thresholds for statistical signal detection with the proportional reporting ratio.
    Slattery J; Alvarez Y; Hidalgo A
    Drug Saf; 2013 Aug; 36(8):687-92. PubMed ID: 23754759
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Are finasteride-related penile curvature/Peyronie's disease Adverse Event Reports worthy of further clinical investigation? Disproportionality analysis based on both the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) pharmacovigilance databases.
    Schifano N; Capogrosso P; Boeri L; Fallara G; Chiappini S; Rewhorn M; Cakir OO; Harvey H; Castiglione F; Alnajjar HM; Muneer A; Deho' F; Schifano F; Montorsi F; Salonia A
    Int J Impot Res; 2023 Aug; 35(5):465-471. PubMed ID: 35513712
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enhanced Paediatric Pharmacovigilance at the European Medicines Agency: A Novel Query Applied to Adverse Drug Reaction Reports.
    Blake KV; Saint-Raymond A; Zaccaria C; Domergue F; Pelle B; Slattery J
    Paediatr Drugs; 2016 Feb; 18(1):55-63. PubMed ID: 26597489
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Licensing of Orphan Medicinal Products-Use of Real-World Data and Other External Data on Efficacy Aspects in Marketing Authorization Applications Concluded at the European Medicines Agency Between 2019 and 2021.
    Naumann-Winter F; Wolter F; Hermes U; Malikova E; Lilienthal N; Meier T; Kalland ME; Magrelli A
    Front Pharmacol; 2022; 13():920336. PubMed ID: 36034814
    [No Abstract]   [Full Text] [Related]  

  • 33. Cardiac Events Potentially Associated to Remdesivir: An Analysis from the European Spontaneous Adverse Event Reporting System.
    Rafaniello C; Ferrajolo C; Sullo MG; Gaio M; Zinzi A; Scavone C; Gargano F; Coscioni E; Rossi F; Capuano A
    Pharmaceuticals (Basel); 2021 Jun; 14(7):. PubMed ID: 34202350
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Benefits of combining change-point analysis with disproportionality analysis in pharmacovigilance signal detection.
    Trinh NTH; Solé E; Benkebil M
    Pharmacoepidemiol Drug Saf; 2019 Mar; 28(3):370-376. PubMed ID: 29992679
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real World Data on the Utilization Pattern and Safety Profile of Infliximab Originator Versus Biosimilars in Italy: A Multiregional Study.
    Scavone C; Sessa M; Clementi E; Corrao G; Leone R; Mugelli A; Rossi F; Spina E; Capuano A
    BioDrugs; 2018 Dec; 32(6):607-617. PubMed ID: 30341487
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patient Reporting in the EU: Analysis of EudraVigilance Data.
    Banovac M; Candore G; Slattery J; Houÿez F; Haerry D; Genov G; Arlett P
    Drug Saf; 2017 Jul; 40(7):629-645. PubMed ID: 28417320
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Individual Case Safety Report Replication: An Analysis of Case Reporting Transmission Networks.
    van Stekelenborg J; Kara V; Haack R; Vogel U; Garg A; Krupp M; Gofman K; Dreyfus B; Hauben M; Bate A
    Drug Saf; 2023 Jan; 46(1):39-52. PubMed ID: 36565374
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A potential event-competition bias in safety signal detection: results from a spontaneous reporting research database in France.
    Salvo F; Leborgne F; Thiessard F; Moore N; Bégaud B; Pariente A
    Drug Saf; 2013 Jul; 36(7):565-72. PubMed ID: 23673817
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pooling Different Safety Data Sources: Impact of Combining Solicited and Spontaneous Reports on Signal Detection In Pharmacovigilance.
    Jokinen JD; Walley RJ; Colopy MW; Hilzinger TS; Verdru P
    Drug Saf; 2019 Oct; 42(10):1191-1198. PubMed ID: 31190237
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Masking by vaccines in pediatric drug safety signal detection in the EudraVigilance database.
    Dodd C; Pacurariu A; Osokogu OU; Weibel D; Ferrajolo C; Vo DH; Becker B; Kors JA; Sturkenboom M
    Pharmacoepidemiol Drug Saf; 2018 Nov; 27(11):1249-1256. PubMed ID: 30066460
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.